Selected research
Industry Research
Nimodipine Industry Research Report 2026
Market perspective
The global Nimodipine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nimodipine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nimodipine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nimodipine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nimodipine include Yangtze River Pharmaceutical, Shandong Xinhua Pharmaceutical, Sichuan Kelun Pharmaceutical, Hubei Jumpcan Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Cisen Pharmaceutical, Bayer, Bionpharma and Azurity, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nimodipine market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nimodipine Market by Company
Yangtze River Pharmaceutical
Shandong Xinhua Pharmaceutical
Sichuan Kelun Pharmaceutical
Hubei Jumpcan Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Cisen Pharmaceutical
Bayer
Bionpharma
Azurity
Avet Pharmaceuticals Inc.
Nimodipine Segment by Type
Solution
Tablets
Capsule
Nimodipine Segment by Application
Clinics
Hospital
Pharmacy
Others
Nimodipine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nimodipine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nimodipine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nimodipine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nimodipine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nimodipine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nimodipine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Solution
- Tablets
- Capsule
Applications
- Clinics
- Hospital
- Pharmacy
- Others
Companies covered
- Yangtze River Pharmaceutical
- Shandong Xinhua Pharmaceutical
- Sichuan Kelun Pharmaceutical
- Hubei Jumpcan Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Cisen Pharmaceutical
- Bayer
- Bionpharma
- Azurity
- Avet Pharmaceuticals Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nimodipine Market Size (2021-2032)
- 2.2.2 Global Nimodipine Sales (2021-2032)
- 2.2.3 Global Nimodipine Market Average Price (2021-2032)
- 2.3 Nimodipine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Solution
- 2.3.3 Tablets
- 2.3.4 Capsule
- 2.4 Nimodipine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinics
- 2.4.3 Hospital
- 2.4.4 Pharmacy
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nimodipine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nimodipine Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Nimodipine Revenue of Manufacturers (2021-2026)
- 3.4 Global Nimodipine Average Price by Manufacturers (2021-2026)
- 3.5 Global Nimodipine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nimodipine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nimodipine, Product Type & Application
- 3.8 Global Manufacturers of Nimodipine, Established Date
- 3.9 Global Nimodipine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yangtze River Pharmaceutical
- 4.1.1 Yangtze River Pharmaceutical Company Information
- 4.1.2 Yangtze River Pharmaceutical Business Overview
- 4.1.3 Yangtze River Pharmaceutical Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yangtze River Pharmaceutical Nimodipine Product Portfolio
- 4.1.5 Yangtze River Pharmaceutical Recent Developments
- 4.2 Shandong Xinhua Pharmaceutical
- 4.2.1 Shandong Xinhua Pharmaceutical Company Information
- 4.2.2 Shandong Xinhua Pharmaceutical Business Overview
- 4.2.3 Shandong Xinhua Pharmaceutical Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shandong Xinhua Pharmaceutical Nimodipine Product Portfolio
- 4.2.5 Shandong Xinhua Pharmaceutical Recent Developments
- 4.3 Sichuan Kelun Pharmaceutical
- 4.3.1 Sichuan Kelun Pharmaceutical Company Information
- 4.3.2 Sichuan Kelun Pharmaceutical Business Overview
- 4.3.3 Sichuan Kelun Pharmaceutical Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sichuan Kelun Pharmaceutical Nimodipine Product Portfolio
- 4.3.5 Sichuan Kelun Pharmaceutical Recent Developments
- 4.4 Hubei Jumpcan Pharmaceutical
- 4.4.1 Hubei Jumpcan Pharmaceutical Company Information
- 4.4.2 Hubei Jumpcan Pharmaceutical Business Overview
- 4.4.3 Hubei Jumpcan Pharmaceutical Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hubei Jumpcan Pharmaceutical Nimodipine Product Portfolio
- 4.4.5 Hubei Jumpcan Pharmaceutical Recent Developments
- 4.5 Jiangsu Hengrui Pharmaceuticals
- 4.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.5.3 Jiangsu Hengrui Pharmaceuticals Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangsu Hengrui Pharmaceuticals Nimodipine Product Portfolio
- 4.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.6 Cisen Pharmaceutical
- 4.6.1 Cisen Pharmaceutical Company Information
- 4.6.2 Cisen Pharmaceutical Business Overview
- 4.6.3 Cisen Pharmaceutical Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cisen Pharmaceutical Nimodipine Product Portfolio
- 4.6.5 Cisen Pharmaceutical Recent Developments
- 4.7 Bayer
- 4.7.1 Bayer Company Information
- 4.7.2 Bayer Business Overview
- 4.7.3 Bayer Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bayer Nimodipine Product Portfolio
- 4.7.5 Bayer Recent Developments
- 4.8 Bionpharma
- 4.8.1 Bionpharma Company Information
- 4.8.2 Bionpharma Business Overview
- 4.8.3 Bionpharma Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bionpharma Nimodipine Product Portfolio
- 4.8.5 Bionpharma Recent Developments
- 4.9 Azurity
- 4.9.1 Azurity Company Information
- 4.9.2 Azurity Business Overview
- 4.9.3 Azurity Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Azurity Nimodipine Product Portfolio
- 4.9.5 Azurity Recent Developments
- 4.10 Avet Pharmaceuticals Inc.
- 4.10.1 Avet Pharmaceuticals Inc. Company Information
- 4.10.2 Avet Pharmaceuticals Inc. Business Overview
- 4.10.3 Avet Pharmaceuticals Inc. Nimodipine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Avet Pharmaceuticals Inc. Nimodipine Product Portfolio
- 4.10.5 Avet Pharmaceuticals Inc. Recent Developments
5 Global Nimodipine Market Scenario by Region
- 5.1 Global Nimodipine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nimodipine Sales by Region: 2021-2032
- 5.2.1 Global Nimodipine Sales by Region: 2021-2026
- 5.2.2 Global Nimodipine Sales by Region: 2027-2032
- 5.3 Global Nimodipine Revenue by Region: 2021-2032
- 5.3.1 Global Nimodipine Revenue by Region: 2021-2026
- 5.3.2 Global Nimodipine Revenue by Region: 2027-2032
- 5.4 North America Nimodipine Market Facts & Figures by Country
- 5.4.1 North America Nimodipine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nimodipine Sales by Country (2021-2032)
- 5.4.3 North America Nimodipine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Nimodipine Market Facts & Figures by Country
- 5.5.1 Europe Nimodipine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nimodipine Sales by Country (2021-2032)
- 5.5.3 Europe Nimodipine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Nimodipine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nimodipine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nimodipine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nimodipine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nimodipine Market Facts & Figures by Country
- 5.7.1 South America Nimodipine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nimodipine Sales by Country (2021-2032)
- 5.7.3 South America Nimodipine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Nimodipine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nimodipine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nimodipine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nimodipine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Nimodipine Sales by Type (2021-2032)
- 6.1.1 Global Nimodipine Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Nimodipine Sales Market Share by Type (2021-2032)
- 6.2 Global Nimodipine Revenue by Type (2021-2032)
- 6.2.1 Global Nimodipine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nimodipine Revenue Market Share by Type (2021-2032)
- 6.3 Global Nimodipine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nimodipine Sales by Application (2021-2032)
- 7.1.1 Global Nimodipine Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Nimodipine Sales Market Share by Application (2021-2032)
- 7.2 Global Nimodipine Revenue by Application (2021-2032)
- 7.2.1 Global Nimodipine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nimodipine Revenue Market Share by Application (2021-2032)
- 7.3 Global Nimodipine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nimodipine Value Chain Analysis
- 8.1.1 Nimodipine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nimodipine Production Mode & Process
- 8.2 Nimodipine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nimodipine Distributors
- 8.2.3 Nimodipine Customers
9 Global Nimodipine Analyzing Market Dynamics
- 9.1 Nimodipine Industry Trends
- 9.2 Nimodipine Industry Drivers
- 9.3 Nimodipine Industry Opportunities and Challenges
- 9.4 Nimodipine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst